Bringing B7-H4 Antibody-Drug Conjugates to the Forefront of Gynecologic Cancers

Dana M. Chase, MD, joins Angeles Alvarez Secord, MD, MHSc, to discuss mocertatug rezetecan in gynecologic malignancies.

Angeles Alvarez Secord, MD, MHSc, discusses the rationale behind the phase 1/2 BEHOLD-2 trial evaluating mocertatug rezetecan plus dostarlimab in endometrial cancer.

The B7-H4–targeted ADC produced ORRs of 62% and 67% in patients with PROC and endometrial cancer, respectively, in the phase 1 BEHOLD-1 study.